40 results about "Pro calcitonin" patented technology

The invention belongs to the technical field of in-vitro diagnosis and rapid detection, and relates to an interleukin 6 and procalcitonin joint detection kit, a preparation method and a detection method, the interleukin 6 and procalcitonin joint detection kit comprises a Ra1 reagent, a Ra2 reagent, an Rb1 reagent, an Rb2 reagent and a substrate solution; the Ra1 reagent is an interleukin 6 antibody magnetic bead labeling solution, and is prepared from a biotin labeled interleukin 6 first antibody solution and a streptavidin magnetic bead solution; the Ra2 reagent is a procalcitonin antibody magnetic bead labeling solution, and is prepared from a biotin labeled procalcitonin first antibody solution and a streptavidin magnetic bead solution; the Rb1 reagent is prepared from an alkaline phosphatase labeled interleukin 6 second antibody solution; the Rb2 reagent is prepared from a second procalcitonin antibody solution labeled by horse radish peroxidase; the substrate solution comprises a first substrate solution and a second substrate solution. The detection sensitivity can be improved, the detection time is shortened, the detection efficiency is improved, and the operation is simple.

The present invention belongs to the field of clinical diagnosis. In particular, the present invention relates to assessing the severity of a subject suspected of infection or having an infection by determining the level of procalcitonin (hereinafter: PCT) (SEQ ID No: 1) and / or proadrenomedullin (hereinafter: proADM) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular mid-region proadrenomedullin (MR-proADM) (SEQ ID No: 2) in a patient sample, wherein the subject may have physiological signs of infection or increased risk factors, in particular from an infectious disease, and the present invention relates to its workflow. In addition, the present invention relates to assessments related to infection, such as exclusion / determination of patients and stratification, risk assessment, in particular to avoid re-hospitalization and hospital and post-discharge deaths.

The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.

The present invention discloses an anti-procalcitonin antibody or a reagent and kit for detecting procalcitonin, relating to the field of antibodies. The anti-procalcitonin antibody disclosed in the present invention comprises a heavy chain complementary determining region and a light chain complementary determining region. The antibody provides an important source of raw materials for the detection of procalcitonin and has good affinity or activity.

This invention relates to the field of biomedical data processing technology, specifically to a stratification system for sepsis-related secondary invasive fungal infections based on laboratory data. The invention obtains the degree of static intestinal baseline damage by considering serum lactate concentrations at different historical testing times, temporal characteristics, and a preset maximum backtracking period; it obtains the cumulative dosage of antimicrobial drugs and the hourly cumulative distribution value of drug use based on the drug dosage distribution at different medication times within a neighborhood of the real-time trigger time; it obtains the overall degree of inflammation reduction and the hourly cumulative distribution value of inflammation regression based on the procalcitonin concentration distribution at testing times within a neighborhood; and it further obtains the net drug-induced intervention level. Based on the degree of static intestinal baseline damage and the net drug-induced intervention level, the fungal infection characteristics are stratified. This invention, by considering non-drug-induced interference, accurately obtains the comprehensive risk level of fungal infection, improving the effectiveness of fungal infection stratification.

The invention discloses a procalcitonin electrochemical luminescence detection kit. The kit comprises a magnetic microsphere reagent coated by a procalcitonin capture antibody and a procalcitonin detection antibody reagent labeled by an electrically neutral ruthenium compound, the structural general formula of the electrically neutral ruthenium compound is # imgabs0 # n = 0-9; the magnetic microsphere reagent coated with the procalcitonin capture antibody comprises magnetic microspheres coated with the procalcitonin capture antibody and a diluent; the electrically neutral ruthenium compound labeled procalcitonin detection antibody reagent comprises an electrically neutral ruthenium compound labeled procalcitonin detection antibody and a diluent; the diluent is prepared from piperazine-1, 4-diethyl sulfonic acid or 3-[N-N-bis (2-ethoxyl) amino]-2-hydroxy propanesulfonic acid. When the procalcitonin electrochemical luminescence detection kit is used for detection, a reaction system does not contain streptavidin-coated magnetic beads or biotinylated antibodies, so that interference of biotin possibly existing in a sample on a test result is effectively avoided, and wide application can be realized.

The present invention discloses a non-interfering SERS probe, a preparation method and an application thereof, which relate to the technical field of surface-enhanced Raman spectroscopy detection. The Raman characteristic peak of the SERS probe of the present invention is in the range of 1800 cm-1 - 2500 cm-1 of the Raman silent region; the SERS probe includes a colloidal gold structure, a silver shell disposed on the surface of the colloidal gold structure, and a plurality of Raman reporter molecules phenylacetylene connected to the silver shell. The outer side of the phenylacetylene is connected with a polydopamine layer formed by self-polymerization of dopamine, and the outer side of the polydopamine layer is connected with a procalcitonin antibody. The probe of the present invention has good stability and reproducibility and strong optical response; it can solve the problem that the SERS probe is easily optically interfered by endogenous biomolecules in the fingerprint region (300 - 1800 cm-1), resulting in a reduction in the accuracy of quantitative analysis, and has good application prospects in the field of single / multiple index quantitative analysis.

The present invention discloses a method for PEG site-specific modification of inflammatory markers and increasing protein stability, comprising the following steps: a purified protein in procalcitonin, C-reactive protein, amyloid A or interleukin 6 is mixed with mPEG2000Mal in a 5mmol / L phosphate buffer having a pH value of 7.2-7.4 until the reaction is complete. The conjugate is purified by a chromatographic column, and then rinsed by a proportioning liquid until it is flushed flat; then the proportioning liquid is used for elution, so that the sample is collected when the absorbance of the product increases; the collected sample is placed in an ultrafiltration centrifuge tube and centrifuged by a centrifugal device. The present invention selects a peg with a molecular weight of 2000, because its molecular weight is relatively small, it can partially penetrate into the protein for modification, which can also reduce immunogenicity relatively less while increasing protein stability.

The present invention relates to the field of antibody technology, and in particular to anti-procalcitonin antibodies and applications thereof. The amino acid sequences of the heavy chain complementary determining regions CDR1, CDR2, and CDR3 of the antibody or antigen-binding fragment thereof provided by the present invention are shown in SEQ ID NO.1-3, and the amino acid sequences of the light chain complementary determining regions CDR1, CDR2, and CDR3 are shown in SEQ ID NO.4-6. The antibody can specifically bind to procalcitonin and has a high affinity. The immunoassay reagent developed using the antibody has high specificity and sensitivity when used for procalcitonin detection, and has a high consistency with the reference detection method, can more accurately reflect the procalcitonin content of real samples, and has a wide range of application prospects in the field of immunoassay of procalcitonin.

The application discloses an inflammation infection compound quality control product and a preparation method and application thereof. The quality control product comprises a matrix liquid and inflammation markers. The matrix liquid contains human serum, a buffer, a protein protective agent, a plasticizing agent, amino acids, saccharides, a surfactant and a preservative. The inflammation markers include C-reactive protein, procalcitonin, serum amyloid A and interleukin-6. The quality control product is stable in performance, can be placed for 1 year under 2-8 DEG C and in the dark, and is suitable for combined detection of different inflammation items, is convenient for clinical operation, saves cost, and provides guarantee for the accuracy of clinical test results.

The presently claimed and described technology provides methods for chemiluminescence-based assays employing 1,2 dioxetane compounds. In some instances, the analyte is cardiac troponin I (TNI), Thyroid-stimulating Hormone (TSH), or procalcitonin (PCT). Methods disclosed herein comprise: exposing a biological sample to a capture antibody configured to bind to at least one portion of an analyte disclosed herein generating a first reaction mixture; exposing the first reaction mixture to an enzyme-conjugated affinity molecule, forming a second reaction mixture; exposing the second reaction mixture to a substrate formulation comprising a 1,2 dioxetane compound disclosed herein; wherein the reaction between the enzyme-conjugated affinity molecule and the substrate formulation generates a chemiluminescent detection signal; recording the detection signal generated by the reaction; and comparing the recorded signal to a calibration curve to quantify the level of the analyte in the biological sample.

The invention provides a fusion polypeptide, a kit and a detection method for procalcitonin detection. The provided SCFV antibodies fused to the large subunit and the small subunit of luciferase respectively can provide the best detection effect. When the fusion polypeptide is used for detecting the procalcitonin or the analogue thereof, excellent clinical comparison correlation is achieved, the detection time is shorter, the detection speed is higher, and a matched instrument is simple in structure.

The present invention discloses a test strip for the combined detection of heparin-binding protein (HBP) / procalcitonin (PCT) in peripheral blood, a preparation method thereof, and an application thereof. The test strip comprises a PVC base plate, a nitrocellulose membrane, a glass cellulose membrane conjugate pad, a sample pad, and a water-absorbing pad, wherein the PVC base plate is located at the bottom, and a sample pad, a glass cellulose membrane conjugate pad, a nitrocellulose membrane, and a water-absorbing pad are sequentially arranged above the PVC base plate; the nitrocellulose membrane has HBP, PCT detection lines, and a mouse anti-DNP monoclonal antibody quality control line; the glass nitrocellulose membrane conjugate pad has a fluorescent microsphere-labeled HBP antibody, PCT antibody, and a fluorescent microsphere-labeled DNP-BSA conjugate combination. The test strip utilizes the principle of a double antibody sandwich method combined with the characteristics of fluorescent microspheres to perform a fluorescent immunochromatography method, thereby achieving rapid, specific, simple, and sensitive combined detection of HBP and PCT.

The invention discloses a chemiluminiscence detection kit for calcitonin. The chemiluminiscence detection kit comprises carboxyl magnetic nanoparticles coated by streptavidin, a calcitonin monoclonal antibody-1 labeled by acridinium ester, and a calcitonin monoclonal antibody-2 labeled by biotin. According to the chemiluminiscence detection kit for the calcitonin, the chemical substances, namely the cane sugar and the benzamidine hydrochloride, are added into the reagent, so that the influence of the procalcitonin in a sample on a test is reduced, and the stability and the specificity of the kit are greatly improved.

The present invention belongs to the field of in vitro detection technology, and in particular to a homogeneous chemiluminescence assay kit for procalcitonin. The procalcitonin test kit of the present invention includes R1 reagent and R2 reagent independently of each other, wherein the R1 reagent includes luminescent particles coated with procalcitonin monoclonal antibody, surfactant A and stabilizer, and the R2 reagent includes biotin-labeled procalcitonin monoclonal antibody and surfactant B, wherein the surfactant A includes a mixture of Tween 80 and PVP K30 in a mass ratio of 1-2:1, and the surfactant B includes a mixture of Triton x-100 and polyoxyethylene alkyl ether EMULGEN 709 in a mass ratio of 1:2-4. After adding surfactant A and surfactant B in a specific mass ratio, the present invention can exert a good component enhancement effect; by reasonably controlling the content of each substance in R1 reagent and R2, the accuracy, precision, stability and specificity of the procalcitonin assay kit are improved, and the linear relationship is good, which meets clinical needs.

A kit is disclosed for distinguishing between bacterial and viral infections. One of the antibodies of the kit specifically binds to TNF-related apoptosis-inducing ligand (TRAIL) protein and another of the antibodies of the kit specifically binds to Procalcitonin (PCT) protein.

This invention discloses antibodies against procalcitonin or reagents and kits for detecting procalcitonin, relating to the field of antibodies. The anticalcitonin antibody disclosed in this invention includes a heavy chain complementarity-determining region and a light chain complementarity-determining region. This antibody provides an important source of raw materials for the detection of procalcitonin and exhibits good affinity or activity.

The invention relates to a procalcitonin detection kit as well as a preparation method and application thereof. The kit provided by the invention comprises a first antibody coated on magnetic microspheres, a second antibody marked with a tracing marker and a calibrator, the specific binding sites of the procalcitonin identified by the first antibody and the second antibody are different; the calibrator comprises a procalcitonin antigen A and a diluent, the procalcitonin antigen A has a sequence as shown in SEQ ID NO: 1, and the diluent comprises a buffer solution and a protein stabilizer. The calibration product is high in storage stability, the kit is low in matrix effect, and a detection result can be rapidly obtained.

The present invention discloses an anti-procalcitonin Fab antibody and a preparation method and application thereof, wherein the heavy chain variable region of the heavy chain has three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences thereof are shown in SEQ ID NO.1, 2 and 3 respectively; the light chain variable region of the light chain has three complementary determining regions CDR1', CDR2' and CDR3', and the amino acid sequences thereof are shown in SEQ ID NO.4, 5 and 6. The anti-procalcitonin Fab antibody provided by the scheme of the present invention is a fully human genetic engineering antibody, which can be effectively used to detect procalcitonin, and can also be used as a labeling antibody to be paired with other mouse PCT IgG monoclonal antibodies for clinical detection, and has the characteristics of high specificity, high sensitivity, low cost, strong anti-interference ability, etc.

This invention discloses nucleic acid fragments, recombinant vectors, recombinant cells, and recombinant procalcitonin antigen, as well as their preparation methods and applications, relating to the field of procalcitonin preparation. The amino acid sequence of the recombinant procalcitonin antigen is shown in SEQ ID NO: 1, or the amino acid sequence of the recombinant procalcitonin antigen is obtained by attaching a protein purification tag to the C-terminus or N-terminus of the amino acid sequence shown in SEQ ID NO: 1. The recombinant procalcitonin antigen provided by this invention has higher expression levels and purity.

Based on the current situation that no nano antibody aiming at a procalcitonin (PCT) target spot is disclosed in the field, the invention develops an anti-PCT nano antibody which has relatively good binding activity and relatively good binding sensitivity and is simple and convenient to produce, and the anti-PCT nano antibody comprises a detection nano antibody and a coating nano antibody; the nano antibody for specifically targeting PCT provided by the invention meets the requirements on diagnosis sensitivity and precision, and has relatively high application potential in the field of detection.

The application belongs to the technical field of microorganisms, and specifically discloses a fermented Lactobacillus muciapparius BLF03 and application thereof in resisting drug-resistant Staphylococcus aureus. The drug-resistant Staphylococcus aureus is Staphylococcus aureus resistant to drugs targeting beta-lactamase. The fermented Lactobacillus muciapparius BLF03 has been preserved in the China General Microbiological Culture Collection Center on November 6, 2025, and the preservation number is CGMCC No. 36521. The application provides the fermented Lactobacillus muciapparius BLF03 for resisting Staphylococcus aureus resistant to drugs targeting beta-lactamase, which can well relieve infection symptoms induced by drug-resistant Staphylococcus aureus, reduce the expression level of procalcitonin in the body after infection, and improve inflammatory stress response caused by infection, thereby providing a new safe and efficient strain selection for products resisting drug-resistant Staphylococcus aureus.

The present application relates to a kind of acceptor reagent in the preparation for the use of kit for the method for diagnosing whether subject is infected bacterial inflammatory disease in vitro, wherein the method comprises: the body fluid from subject is contacted with acceptor reagent and donor reagent, and generates the mixture to be measured after reaction;The intensity of the chemiluminescence signal generated thereby is detected by exciting the mixture to be measured at least once with excitation light;The concentration of procalcitonin in the body fluid is quantitatively calculated according to the intensity of the chemiluminescence signal, to determine whether subject is infected bacterial inflammatory disease;Wherein, the acceptor reagent comprises the acceptor particle capable of generating chemiluminescence by reacting with active oxygen, and the particle size distribution variation coefficient C.V value of the acceptor particle in acceptor reagent is controlled to be greater than or equal to 5%;The donor reagent comprises donor particle capable of generating active oxygen under excitation state.The method has both ultra-high sensitivity and very wide detection range.

The present invention provides an anti-procalcitonin antibody. The present invention also provides a detection kit comprising the anti-procalcitonin antibody. The anti-procalcitonin antibody provided by the present invention has high affinity and specificity for the binding of procalcitonin and can be used for detecting the level of anti-procalcitonin in serum.

The invention discloses a time-resolved fluorescence immunoassay test strip for joint detection of procalcitonin (PCT) / interleukin-6 (IL-6) in peripheral blood as well as a preparation method and application of the time-resolved fluorescence immunoassay test strip. The technical field belongs to the technical field of biological detection, the existing lateral flow chromatography technology has the problems of narrow linear range, low specificity, poor accuracy, low sensitivity, poorer repeatability (interference) and the like, and aiming at the defects in the prior art, the technical scheme is as follows: a double-antibody sandwich method principle is combined with the characteristics of time-resolved fluorescent microspheres, and the time-resolved fluorescent microspheres are used for detecting the time-resolved fluorescent microspheres. Based on a lateral flow immunochromatography method, rapid, specific, accurate, sensitive, simple and convenient combined detection on PCT and IL-6 in peripheral blood is realized at the same time, and reproducibility is good.

The utility model discloses a procalcitonin and interleukin 6 joint detection kit which comprises a kit body and a cover body, an observation opening is formed in the top of one end of the kit body, a sample adding opening is formed in the top of one end, far away from the observation opening, of the kit body, and a detection card containing a fluorescein labeled conjugate of a procalcitonin antibody and an interleukin 6 antibody is installed in the kit body. The detection card contains a fluorescein labeled conjugate containing a procalcitonin antibody and an interleukin antibody, the sample adding port is communicated with the detection card, a slot is formed in one side, close to the box body, of the cover body, and one end, close to the sample adding port, of the box body can be inserted into the slot. By arranging the cover body which can be clamped on the box body, the cover body can effectively protect the sample adding opening from being polluted, and the purity of a blood sample is guaranteed; by arranging the heating bag, after the cover body is opened, the heating bag is in contact with the outside to generate heat, so that a blood sample stably reacts with the detection card, and meanwhile, as the heating bag only heats for a certain time, a timing effect can be achieved.

The invention discloses an anti-procalcitonin antibody and application thereof, and relates to the field of antibodies. The anti-procalcitonin antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of procalcitonin, and has good affinity or activity.

The invention discloses a prediction model for early warning of leukemia sepsis, and belongs to the technical field of medical information. Immunosuppression and infection of leukemia patients are rapidly deteriorated, and existing indexes and models are low in sensitivity and difficult to recognize sepsis in time. According to the system, eight conventional indexes, namely C reactive protein, procalcitonin, neutrophil counting, lymphocyte counting, thrombin time, red blood cell counting, total bile acid and systolic pressure, of the first day of admission are extracted, key features are screened through single-factor logistic regression, LASSO and Boruta algorithms in a combined mode, a random forest model is trained, and 10-fold cross validation and grid search optimization are conducted; a nonlinear relation is analyzed by combining SHAP explanation and a restrictive cubic spline, AUC0.765 is trained, AUC0.700 is verified, individualized risk scoring is provided, a hospital information system is embedded, clinical early intervention is guided, and death is reduced.

The present application relates to the field of medical immunodetection, in particular to procalcitonin latex immunoturbidimetry detection reagent combination and application thereof. The present application provides procalcitonin latex immunoturbidimetry detection reagent combination comprising R1 reagent and R2 reagent and application thereof. The present application adopts latex immunoturbidimetry, and further provides procalcitonin latex immunoturbidimetry detection reagent combination with good stability, high precision, high accuracy, high anti-interference and high linear range level by optimizing reaction system and proportion of each component, which is conducive to the popularization and application of the reagent in clinic.